 Home > Active Ingredient News > Study of Nervous System > The first domestic hormone replacement therapy for the treatment of hypoparathyroidism was approved for Phase III...

The first domestic hormone replacement therapy for the treatment of hypoparathyroidism was approved for Phase III...

 Last Update: 2021-06-08
 Source: Internet
 Author: User

Tags

libtayo fda approval

united states industries

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

June 2nd, Shanghai, China/June 1st each year, is World Hypoparathyroidism Day.

Hypoparathyroidism (HP) is a group of clinical syndromes caused by undersecretion and/or insufficient effect of parathyroid hormone (PTH).

The PaTHway China trial is designed to evaluate the possibility of TransCon™ parathyroid hormone as a hormone replacement therapy.

The key secondary efficacy endpoints of PaTHway China include the evaluation of patients receiving TransCon™ parathyroid hormone, the changes in the scores of the "Hypoparathyroidism Patient Experience Scale (HPES)" and the "36 Health Survey Summary".

Dr.

Previously, data from Ascendis Pharma's global Phase II clinical study of TransCon™ parathyroid hormone (PaTH Forward study) has demonstrated the potential of TransCon™ parathyroid hormone as a replacement therapy for HP.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The first domestic hormone replacement therapy for the treatment of hypoparathyroidism was approved for Phase III clinical press release

06-18

Related Products

Scopolamine hot sale CAS 51-34-3 wholesale Scopolamine powder

CAS No.: 51-34-3

Pharmacy Grade

$3.2-3.5/KG FOB

Paroxetine CAS 61869-08-7

CAS No.: 61869-08-7

Pharmacy Grade

$88-98/KG FOB

Scopolamine Hydrobromide CAS 114-49-8

CAS No.: 114-49-8

Pharmacy Grade

$118-128/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

The first domestic hormone replacement therapy for the treatment of hypoparathyroidism was approved for Phase III...

Related Articles

The first domestic hormone replacement therapy for the treatment of hypoparathyroidism was approved for Phase III clinical press release